Agenus Inc. (AGEN) CEO Garo Armen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Agenus Announces First Patient Dosed in Phase 1 Study of AGEN1571 (anti-ILT2) in Advanced Solid TumorsGlobeNewsWire • 08/01/22
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal CancerBenzinga • 06/29/22
Agenus Shows Unprecedented Activity for Botensilimab/Balstilimab Combination in Microsatellite Stable Colorectal Cancer at ESMO World GI CongressGlobeNewsWire • 06/29/22
Agenus to Host Investor Webcast to Review Late-Breaking Botensilimab and Balstilimab Data Presented at ESMO World GI CongressGlobeNewsWire • 06/21/22
GSK's RSV vaccine candidate for older adults, containing Agenus' QS-21 STIMULON™ as part of GSK's AS01 adjuvant, reports positive pivotal data supporting initiation of global regulatory submissionsGlobeNewsWire • 06/10/22
Agenus Announces Late-Breaking Oral Presentation at ESMO-GI and Strategies to Advance BotensilimabGlobeNewsWire • 05/24/22
Agenus Inc. (AGEN) CEO Garo Armen on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
Why Adaptimmune Therapeutics, Agenus, and Sorrento Therapeutics Popped TodayThe Motley Fool • 04/19/22
Agenus Presents Data on AGEN1571 (anti-ILT2) at AACR and Announces IND ClearanceGlobeNewsWire • 04/08/22